ASCO sharpens breast cancer follow-up around recurrence risk, not routine intensity alone
ASCO has updated its guidance on breast cancer follow-up after primary treatment, placing routine surveillance on a narrower, more clinically grounded track. The new recommendations continue to center on regular history, physical examination, and mammography, while acknowledging that the cadence of follow-up should become more individualized in patients carrying a higher risk of recurrence.
The document matters because survivorship care has long been pulled in two directions: patients want reassurance and early detection, while clinicians have to avoid surveillance patterns that add burden without proven benefit. In this update, the panel made clear that the foundation of follow-up remains familiar, but the degree of intensity should reflect relapse risk and treatment history rather than a one-size-fits-all schedule.
Limited trial evidence left consensus to do much of the work
The evidence base behind the update was strikingly thin. A single randomized controlled trial provided the evidentiary support for the mammography recommendation, and no randomized trials were identified that compared different follow-up strategies by relapse risk in people treated for early-stage breast cancer. With so little direct comparative evidence, the panel relied on a formal modified Delphi consensus process to shape recommendations.
That scarcity of trial data has direct clinical consequences. In the absence of robust head-to-head studies, follow-up after curative-intent therapy can drift into habit, local custom, or patient anxiety rather than evidence. ASCO’s update draws a firmer line around what should happen routinely and what should be tailored, especially in patients whose recurrence risk is not uniform across the survivorship population.
Regular surveillance still starts with the bedside encounter. History and physical examination remain central, and mammography continues to anchor imaging follow-up after primary treatment. The recommendation to allow either virtual or in-person visits adds practical flexibility, especially for patients who are clinically stable, geographically distant, or balancing work, caregiving, and ongoing recovery.
Risk-based follow-up reflects the biology of relapse
The new guidance gives greater attention to patients whose disease course leaves less margin for clinical delay. Individuals with locally advanced disease or residual disease after neoadjuvant chemotherapy warrant closer surveillance, since both scenarios signal a heavier residual tumor burden and a greater likelihood of occult micrometastatic disease. In practice, these patients are the ones most likely to benefit from a follow-up plan that is tightened rather than relaxed.
Risk-based follow-up also matches the biology of breast cancer recurrence. Residual disease after neoadjuvant treatment is a marker that the tumor has already demonstrated partial therapeutic resistance, and locally advanced presentation reflects a disease process that has already shown aggressive local behavior. Surveillance in these settings is less about routine check-ins and more about maintaining a lower threshold for reassessment when symptoms, exam findings, or imaging raise concern.
The recommendation does not suggest that every high-risk survivor needs a battery of additional tests at every visit. Instead, it supports closer surveillance as a clinical posture, leaving room for judgment about timing, modality, and visit format. In a setting where evidence is limited, that may be the most defensible way to protect patients from both under-monitoring and excessive testing.
Biomarkers and supplemental imaging remain constrained by evidence gaps
ASCO also addressed the use of blood-based biomarkers and supplemental imaging, but the update stops short of endorsing broad, routine escalation. The very inclusion of these topics reflects how often survivors ask whether more testing should mean better detection. The answer remains cautious because extra imaging and biomarker surveillance have not yet accumulated enough high-quality evidence to justify blanket use across all patients.
For clinicians, this restraint is not academic. Ordering additional scans or blood tests after treatment can expose patients to false positives, follow-up cascades, and avoidable anxiety, especially when the pretest probability of actionable recurrence is low. A biomarker drawn without a proven action pathway may create uncertainty rather than clarity, and imaging beyond mammography can quickly move the encounter away from symptom-guided care.
The guideline therefore preserves a conservative framework: routine mammography, regular clinical assessment, and selective intensification for patients who fit a higher-risk profile. It leaves open the possibility that better tools will eventually refine surveillance, but not before stronger evidence is available.
Virtual follow-up is now part of the survivorship conversation
One of the practical updates is the acceptance of either virtual or in-person visits. For many survivors, a video or telephone encounter can preserve continuity without sacrificing the clinical essentials of follow-up, provided symptoms are reviewed carefully and the threshold for in-person examination stays appropriately low.
Virtual follow-up is especially relevant when long-term survivorship care becomes a repeated sequence of low-yield visits. Patients who are asymptomatic and stable may not need every encounter to occur in clinic, as long as the structure of care still allows for exam, imaging review, medication reconciliation, and prompt escalation when new symptoms emerge. The model is not a replacement for physical examination in all cases; it is a way to match visit format to clinical need.
What the update leaves unresolved
The guideline closes one door and leaves another open. It gives clinicians a clearer framework for surveillance after primary treatment, but it also exposes how few randomized data exist on the best way to follow survivors over time. No trial evidence was identified to determine whether different follow-up schedules should vary by relapse risk in early-stage disease, and that gap continues to limit precision.
The most important unanswered questions now sit squarely in front of future research: which patients truly benefit from intensified follow-up, which imaging or biomarker strategies change outcomes rather than simply increasing testing, and how best to personalize surveillance without creating unnecessary clinical friction. Until those data arrive, the safest course remains the one ASCO has chosen here: routine history, physical examination, and mammography, with closer attention reserved for patients whose disease biology places them at higher risk of recurrence.